Products - Dementia | Topic

Showing 14 products

Date | Title

Alzheimer's disease (early) - gantenerumab [ID6142]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Deep Brain Stimulation for Alzheimer
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Dementia (QS184)
Product type:
Quality standard
Published:
28 June 2019
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
Product type:
Guidance
Programme:
NICE guideline
Published:
20 June 2018
Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)
Product type:
Guidance
Programme:
NICE guideline
Published:
20 October 2015
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 March 2025
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 June 2018
Published:
23 March 2011
Gantenerumab for treating early Alzheimer's disease TS ID 10668
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 February 2025
Prevention of dementia
Status:
Awaiting development
Expected publication date:
TBC
Pridopidine for treating Huntington's disease TSID 12052
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Suspected neurological conditions: recognition and referral (NG127)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
1 May 2019
Suspected neurological conditions: recognition and referral (QS198)
Product type:
Quality standard
Published:
8 January 2021

Dementia Products

Filter

Product type

Guidance programme

Status

New and updated

Showing 14 products

Alzheimer's disease (early) - gantenerumab [ID6142]

Deep Brain Stimulation for Alzheimer

Dementia (QS184)

Dementia: assessment, management and support for people living with dementia and their carers (NG97)

Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

Gantenerumab for treating early Alzheimer's disease TS ID 10668

Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]

Prevention of dementia

Pridopidine for treating Huntington's disease TSID 12052

Suspected neurological conditions: recognition and referral (NG127)

Suspected neurological conditions: recognition and referral (QS198)